An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With DSXS in Patients With Atopic Dermatitis.
Phase of Trial: Phase II
Latest Information Update: 07 May 2017
At a glance
- Drugs Desoximetasone (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Taro Pharmaceuticals USA
- 16 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 16 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
- 08 Oct 2016 Planned number of patients changed from 40 to 70.